dm+d

Unassigned

New Medicines

Solucin Gastroenteropancreatic neuroendocrine tumours

Information

Solucin
Radiopharmaceutical
ITM Medical Isotopes GmbH
ITM Medical Isotopes GmbH

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

177Lutetium-mediated beta-irridiation that kills neoplastic cells and malignant tissue
Population-based studies have assessed the incidence of PNETs as 0.2-0.4 per 100,000. However, there is a much higher prevalence of 0.5-1.5% in unselected autopsy specimens. PNETs account for about 3% of all primary pancreatic tumours [1].
Gastroenteropancreatic neuroendocrine tumours
Intravenous infusion